Travere Therapeutics, Inc. announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.655 USD | -0.20% | +11.92% | -14.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.85% | 584M | |
+18.29% | 123B | |
+14.80% | 107B | |
-4.47% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.51% | 16.23B | |
+2.35% | 13.43B | |
+24.25% | 11.32B |
- Stock Market
- Equities
- TVTX Stock
- News Travere Therapeutics, Inc.
- Travere Therapeutics, Inc. Appoints Jula Inrig, M.D., as Chief Medical Officer